AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23393217 — intervention group
Group type: COMPARATOR
Intervention: usual care (wait-list control group)
Number of subjects: 268
Study 21175437 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 8
Study 21175437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pool model with circadian rhythm function
Number of subjects: 8
Study 21175437 — intervention group
Group type: COMPARATOR
Intervention: Both models (AAI and Pool)
Number of subjects: 8
Study 19450116 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of peginterferon alfa-2b + ribavirin
Number of subjects: 0
Study 19450116 — intervention group
Group type: COMPARATOR
Intervention: 24 weeks of peginterferon alfa-2b + ribavirin
Number of subjects: 0
Study 16614779 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml of 0.3 percent nitroglycerin ointment (2.25 mg nitroglycerin) t.i.d. intra‐anal using the cannula (Group A)
Number of subjects: 26
Study 16614779 — intervention group
Group type: COMPARATOR
Intervention: 0.75 ml of 0.3 percent nitroglycerin ointment (2.25 mg nitroglycerin) perianally with the gloved finger (Group B)
Number of subjects: 26
Study 12919338 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interventions for epilepsy (specific interventions not detailed in the abstract)
Number of subjects: 535
Study 12919338 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized (observational) studies
Number of subjects: 535
Study 11026212 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of certainty, view, and attention
Number of subjects: 386
Study 11026212 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of certainty, description, and time
Number of subjects: 386
Study 9542752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g daily) and d-alpha-tocopherol (1000 IU daily)
Number of subjects: 20
Study 9542752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8392820 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication (0.3 mg atropine sulfate and 60 mg pseudoephedrine)
Number of subjects: 43
Study 8392820 — intervention group
Group type: COMPARATOR
Intervention: Control (inert capsules)
Number of subjects: 43
Study 3556983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cisapride (8 mg)
Number of subjects: 12
Study 3556983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29975573 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance-training protocol
Number of subjects: 39
Study 29975573 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-training protocol
Number of subjects: 39
Study 29975573 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 26807898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamellar corneal transplantation (LCT)
Number of subjects: 9
Study 26807898 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 9
Study 26807898 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 9
Study 25529948 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐EAUS
Number of subjects: 100
Study 25529948 — intervention group
Group type: COMPARATOR
Intervention: Routine examinations (digital examination and probe)
Number of subjects: 100
Study 22815422 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivabradine
Number of subjects: 100
Study 22815422 — intervention group
Group type: COMPARATOR
Intervention: Oral metoprolol
Number of subjects: 100
Study 20207878 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass azithromycin distributions (four biannual treatments)
Number of subjects: 24
Study 17050036 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing 2 h after lunch
Number of subjects: 47
Study 17050036 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing when hungry
Number of subjects: 47
Study 17050036 — intervention group
Group type: COMPARATOR
Intervention: No gum chewing
Number of subjects: 47
Study 15977870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1% + phenylephrine 2.5%
Number of subjects: 39
Study 15977870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 1% + phenylephrine 2.5%
Number of subjects: 39
Study 15977870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate 0.2% + phenylephrine 1%
Number of subjects: 39
Study 12077934 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 69
Study 12077934 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 69
Study 7839779 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-nitrous oxide-fentanyl
Number of subjects: 41
Study 7839779 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone-isoflurane-nitrous oxide-fentanyl
Number of subjects: 41
Study 3192871 — intervention group
Group type: EXPERIMENTAL
Intervention: Phazet
Number of subjects: 130
Study 3192871 — intervention group
Group type: COMPARATOR
Intervention: SPTs with standardized extracts
Number of subjects: 130
Study 30785702 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based Ureteral Stent Tracker (UST) application
Number of subjects: 90
Study 30785702 — intervention group
Group type: COMPARATOR
Intervention: Appointment card system
Number of subjects: 90
Study 28463759 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery (RALS)
Number of subjects: 120
Study 28463759 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy (LT)
Number of subjects: 120
Study 26286141 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg once daily
Number of subjects: 717
Study 26286141 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 500/50 mcg twice daily
Number of subjects: 717
Study 23946220 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose valacyclovir (500 mg twice daily)
Number of subjects: 60
Study 23946220 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose valacyclovir (1 g twice daily)
Number of subjects: 60
Study 23946220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21124260 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for predominant leg pain in DS patients
Number of subjects: 1206
Study 21124260 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for predominant leg pain in SpS patients
Number of subjects: 1206
Study 21124260 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for equal pain groups in DS and SpS patients
Number of subjects: 1206
Study 21124260 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment for predominant LBP patients
Number of subjects: 1206
Study 19840652 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal rotary retreatment system
Number of subjects: 40
Study 19840652 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal rotary retreatment system with chloroform
Number of subjects: 40
Study 19840652 — intervention group
Group type: COMPARATOR
Intervention: Gates‐Glidden and K‐files
Number of subjects: 40
Study 19840652 — intervention group
Group type: COMPARATOR
Intervention: Gates‐Glidden and K‐files with chloroform
Number of subjects: 40
Study 16874005 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 100
Study 16874005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 100
Study 15257469 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micro g of budesonide
Number of subjects: 24
Study 15257469 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micro g of budesonide
Number of subjects: 24
Study 15257469 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 11397610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic suppressors (n = 12)
Number of subjects: 21
Study 11397610 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanethidine (n = 6)
Number of subjects: 21
Study 11397610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous regional sympathetic blocks (n = 9)
Number of subjects: 21
Study 11397610 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (n = 5)
Number of subjects: 21
Study 9407327 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA-enriched soft oil capsules administered after each meal daily for 4 weeks
Number of subjects: 21
Study 9407327 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA-enriched soft oil capsules
Number of subjects: 21
Study 9407327 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy subjects without liver disease and gastritis)
Number of subjects: 21
Study 8516523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (4 micrograms/kg) and saline (2 ml)
Number of subjects: 60
Study 8516523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg) and fentanyl (4 micrograms/kg)
Number of subjects: 60
Study 8516523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 60
Study 3044238 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA)
Number of subjects: 0
Study 3044238 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Anaesthesia (EA)
Number of subjects: 0
Study 3044238 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anaesthesia (SA)
Number of subjects: 0
Study 31702673 — intervention group
Group type: EXPERIMENTAL
Intervention: HT048 (1000 mg)
Number of subjects: 120
Study 31702673 — intervention group
Group type: EXPERIMENTAL
Intervention: HT077 (400 mg)
Number of subjects: 120
Study 31702673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25137146 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube cuff pressure maintained at 15 mm Hg
Number of subjects: 50
Study 25137146 — intervention group
Group type: COMPARATOR
Intervention: Control group with cuff pressure monitored without manipulation
Number of subjects: 50
Study 23348809 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib-MenC-TT (6-in-1 group)
Number of subjects: 142
Study 23348809 — intervention group
Group type: COMPARATOR
Intervention: DTPa-IPV-Hib (control group)
Number of subjects: 142
Study 22103814 — intervention group
Group type: EXPERIMENTAL
Intervention: YKL-40 genotype (TT homozygotes)
Number of subjects: 456
Study 22103814 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon/ribavirin therapy
Number of subjects: 456
Study 22103814 — intervention group
Group type: EXPERIMENTAL
Intervention: YKL-40 promoter polymorphism
Number of subjects: 456
Study 19267695 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold ECT (stimulus intensity just above seizure threshold)
Number of subjects: 50
Study 19267695 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold ECT (stimulus intensity 2.5 times seizure threshold)
Number of subjects: 50
Study 17565166 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior Odyssey program
Number of subjects: 0
Study 15208277 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of reproductive health services by GPs
Number of subjects: 198
Study 15208277 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban location of GP clinic
Number of subjects: 198
Study 15208277 — intervention group
Group type: EXPERIMENTAL
Intervention: Female GP
Number of subjects: 198
Study 15208277 — intervention group
Group type: EXPERIMENTAL
Intervention: Postgraduate training in reproductive health
Number of subjects: 198
Study 15208277 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of reproductive health
Number of subjects: 198
Study 11887809 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L exchange
Number of subjects: 12
Study 11887809 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-L exchange
Number of subjects: 12
Study 11887809 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-L exchange
Number of subjects: 12
Study 11887809 — intervention group
Group type: COMPARATOR
Intervention: 2-L exchange (overnight)
Number of subjects: 12
Study 11887809 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L, 2.5-L, and 3-L exchanges
Number of subjects: 12
Study 9777901 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (individual instruction three times per week for 10 weeks)
Number of subjects: 51
Study 9777901 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no specific exercise, wait-listed for intervention)
Number of subjects: 51
Study 7873457 — intervention group
Group type: EXPERIMENTAL
Intervention: formestane (Lentaron) 250 mg every 2 weeks by intramuscular injection
Number of subjects: 409
Study 7873457 — intervention group
Group type: COMPARATOR
Intervention: tamoxifen 30 mg/day orally
Number of subjects: 409
Study 3066848 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 8
Study 29794959 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Cardiopulmonary Assessment (RCPA) performed by senior pediatric residents
Number of subjects: 71
Study 30257919 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduates from top 10 medical schools (USNWR primary care rankings)
Number of subjects: 996212
Study 30257919 — intervention group
Group type: COMPARATOR
Intervention: Graduates from schools ranked ≥50 (USNWR primary care rankings)
Number of subjects: 996212
Study 30257919 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduates from higher ranked medical schools (USNWR research rankings)
Number of subjects: 996212
Study 30257919 — intervention group
Group type: COMPARATOR
Intervention: Graduates from lower ranked medical schools (USNWR research rankings)
Number of subjects: 996212
Study 28855800 — intervention group
Group type: EXPERIMENTAL
Intervention: ESS group (n = 409)
Number of subjects: 1152
Study 28855800 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 326)
Number of subjects: 1152
Study 26296555 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric primary care practice‐based smoking prevention and cessation intervention
Number of subjects: 0
Study 26296555 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23255208 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid-supplemented formula (L1 and L2)
Number of subjects: 0
Study 23255208 — intervention group
Group type: COMPARATOR
Intervention: Control formula (CTRL)
Number of subjects: 0
Study 22204063 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (0.1 mg/kg i.m.)
Number of subjects: 18
Study 22204063 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline i.m.)
Number of subjects: 18
Study 18502208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogens
Number of subjects: 27747
Study 18502208 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg conjugated equine estrogens/d plus 2.5 mg medroxyprogesterone acetate/d)
Number of subjects: 27747
Study 18502208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27747
Study 18502208 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss at 1 year
Number of subjects: 27747
Study 18502208 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain at 1 year
Number of subjects: 27747
Study 18502208 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline obesity (waist circumference >or=114 cm)
Number of subjects: 27747
Study 16979494 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental antiplaque fluoridated formulation
Number of subjects: 14
Study 16979494 — intervention group
Group type: COMPARATOR
Intervention: Fluoridated dentifrice
Number of subjects: 14
Study 16979494 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer cement
Number of subjects: 14
Study 16979494 — intervention group
Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 14
Study 14609886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine hydrochloride, 15 mg/d
Number of subjects: 60
Study 14609886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11206010 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose continuous tamoxifen (200 mg day(-1)), carboplatin (300 mg m(-2) for 3 cycles), and radiotherapy
Number of subjects: 50
Study 11206010 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical control with surgery and radiotherapy only)
Number of subjects: 50
Study 11206010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (tamoxifen, carboplatin, and radiotherapy)
Number of subjects: 50
Study 11206010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 50
Study 8820074 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt rehearsal procedure on a self‐paced, multitrial, free recall task
Number of subjects: 0
Study 8820074 — intervention group
Group type: COMPARATOR
Intervention: Comparison boys
Number of subjects: 0
Study 8820074 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys with ADHD
Number of subjects: 0
Study 1445483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive (30 micrograms ethinyl estradiol + 150 micrograms desogestrel)
Number of subjects: 43
Study 3904389 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 3904389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30375179 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20% CHX + ADS
Number of subjects: 64
Study 30375179 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20% CHX
Number of subjects: 64
Study 30375179 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% CHX + CPC
Number of subjects: 64
Study 29377866 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 0.1 mg/kg (maximum 4 mg) with ropivacaine 0.5% (group D)
Number of subjects: 77
Study 29377866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone 0.1 mg/kg (maximum 4 mg) with ropivacaine 0.5% (group M)
Number of subjects: 77
Study 29377866 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.5% and intramuscular saline (group R)
Number of subjects: 77
Study 26759167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT) with Treatment as Usual (TAU)
Number of subjects: 60
Study 26759167 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study 24626147 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic assessment of asthma-like symptoms and ETS exposure using a brief assessment form at intervention centres
Number of subjects: 7775
Study 24626147 — intervention group
Group type: COMPARATOR
Intervention: Usual care at control centres
Number of subjects: 7775
Study 22007690 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1.0 mg twice daily for 12 weeks with dose titration in the first week
Number of subjects: 36
Study 22007690 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1.0 mg twice daily for 12 weeks
Number of subjects: 36
Study 20214496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin kernel flour-enriched bread
Number of subjects: 88
Study 20214496 — intervention group
Group type: COMPARATOR
Intervention: White bread (control)
Number of subjects: 88
Study 17693333 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Bone Setting (TBS)
Number of subjects: 105
Study 17693333 — intervention group
Group type: COMPARATOR
Intervention: Conventional Physiotherapy (PT)
Number of subjects: 105
Study 17693333 — intervention group
Group type: COMPARATOR
Intervention: Massage (M)
Number of subjects: 105
Study 15100671 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 24
Study 15100671 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 24
Study 15100671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11464257 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 32 mg once daily
Number of subjects: 611
Study 11464257 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg once daily
Number of subjects: 611
Study 11464257 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 611
Study 11464257 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 611
Study 9681128 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (Granocyte) therapy
Number of subjects: 17
Study 9681128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Lenograstim)
Number of subjects: 17
Study 8004326 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-bore (8F) nasogastric tube
Number of subjects: 11
Study 8004326 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-bore (14F) nasogastric tube
Number of subjects: 11
Study 8004326 — intervention group
Group type: COMPARATOR
Intervention: Control (no nasogastric tube)
Number of subjects: 11
Study 2676041 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone plus sexual counselling
Number of subjects: 30
Study 2676041 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus sexual counselling
Number of subjects: 30
Study 2676041 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone alone
Number of subjects: 30
Study 970597 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg atropine i.v. in normothermia
Number of subjects: 25
Study 970597 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg atropine i.v. in hypothermia
Number of subjects: 25
Study 30642386 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose AmBisome therapy
Number of subjects: 0
Study 30642386 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28167194 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training using the Reformer machine
Number of subjects: 24
Study 28167194 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 26063890 — intervention group
Group type: EXPERIMENTAL
Intervention: LET (2.5 mg/daily)
Number of subjects: 107
Study 26063890 — intervention group
Group type: EXPERIMENTAL
Intervention: LET-CYC (LET plus oral cyclophosphamide 50mg/daily)
Number of subjects: 107
Study 23583001 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual reminiscence sessions based on the SolCos model, 6-8 sessions (average 7.4) over 4 weeks
Number of subjects: 82